Esperion Therapeutics' (ESPR) Price Target Reduced to $105 at RBC

UPDATE: Chardan Upgrades Esperion (ESPR) to Neutral But Maintains Negative Bias

(Updated - September 30, 2015 9:31 AM EDT)

Chardan Capital Markets upgraded Esperion Therapeutics (NASDAQ: ESPR) from Sell to Neutral with a price target of $18.00 (from $29.00). The change follows an 84% drop from its May highs at $115.30.

Although he upgraded the stock, analyst Gbola Amusa said he was maintaining his negative bias on concerns related to ETC-1002.

'... we note firstly that ESPR management has to us missed guidance a number of times, and even in our view produced markedly different press releases (on 17 August and on 28 September)... More

Esperion Therapeutics (ESPR) 'Highly Oversold', Needham & Company Says

Needham & Company analyst Chad Messer reiterated a Buy rating and $115 price target on Esperion Therapeutics (NASDAQ: ESPR) as the company is pivoting back toward a dual track Phase III plan focused on approval in both statin-intolerant and statin add-on patients. The analyst views shares as... More

Esperion Therapeutics (ESPR) PT Lowered to $69 at UBS; 'Buy' Maintained

UBS analyst Andrew Peters slashed his price target on Esperion Therapeutics (NASDAQ: ESPR) to $69.00 (from $133.00) but maintained a Buy rating after the company announced updated development plans and timelines following the receipt of minutes from their end-of-ph2 meeting with FDA.

"Notably, while the update does not provide... More

Chardan Capital Cuts PT on Esperion Therapeutics (ESPR) to $29; EOP2 Minutes Worse than Expected

Chardan Capital cuts its price target on Sell-rated Esperion Therapeutics (Nasdaq: ESPR) from $36 down to $29 after the company provided an update on the design and timing of its planned pivotal Phase 3 clinical development program following receipt of the official End-of-Phase 2 Meeting Minutes from the U.S. Food and Drug Administration (FDA).

Analyst Gbola Amusa commented, End-of-phase 2 (EOP2) meeting minutes to us are worse than consensus expected, and even inexplicably inconsistent with prior 17... More

Esperion (ESPR) Gives Update on ETC-1002's Phase 3 Following Receipt of FDA Meeting Minutes

Esperion Therapeutics, Inc. (NASDAQ: ESPR), a pharmaceutical company focused on developing and commercializing a first-in-class, oral therapy for low-density lipoprotein cholesterol (LDL-C) lowering for the treatment of patients with hypercholesterolemia, provided an update on the design and timing of its planned pivotal Phase 3 clinical development program following receipt of the official End-of-Phase 2 Meeting Minutes from the U.S. Food and Drug Administration (FDA).

Esperion plans to conduct multiple Phase 3 clinical trials that will separately evaluate patients with statin intolerance, as well as patients who are inadequately treated despite maximally tolerated statin therapy.... More